Washington Dc, DCNCT04927429Now EnrollingIRB Ready

Cardiovascular Disease Clinical Trial in Washington Dc, DC

Access cutting-edge cardiovascular disease treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.

Sponsored by National Heart, Lung, and Blood Institute (NHLBI)

Quick Self-Assessment

See if you qualify for this Washington Dc location

Preparing your pre-screening questions…

Expert Care in Washington Dc

Access cardiovascular disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cardiovascular disease treatment provided free

Apply for This Washington Dc Location

Check if you qualify for this cardiovascular disease clinical trial in Washington Dc, DC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Washington Dc

    Convenient for DC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Washington Dc site if eligible
  4. 4Begin participation

About This Cardiovascular Disease Study in Washington Dc

Background: In the U.S., over 6.5 million people have heart failure. Researchers want to develop new testing methods for cardiovascular problems using magnetic resonance imaging (MRI) to improve the clinical diagnosis and management of people with heart failure. Objective: To develop and test new methods for imaging the heart and blood vessels using MRI. Eligibility: People ages 18 years and older who are having an MRI of their heart or blood vessels. Healthy volunteers are also needed. Design: Participants will be screened with a medical history. Participants will have a physical exam and blood tests. They will have an electrocardiogram (ECG) to measure the heart s electrical activity. Then they will have their scheduled MRI scan. The MRI scanner is a large, hollow tube. Participants will lie on a table that moves in and out of the tube. During the MRI, they may have contrast dye injected through an intravenous line inserted into their arm or hand. ECG may be used to monitor their heartbeat or coordinate pictures with their heartbeat. A flexible belt may be used to monitor their breathing. A finger probe may be used to track their heart rate and/or oxygenation level. Their blood pressure may be measured. Pictures may be taken of their blood vessels, heart, and lungs before, during, and after they get medicine to increase blood flow. They may lie flat and pedal a stress bicycle to increase their heart rate. Participation will last for 5 years. During that time, participants may receive a yearly survey about their health. They may be contacted for an optional follow-up MRI within 2 years of their MRI.

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Who Can Participate

Inclusion Criteria

Group A: In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Provision of signed and dated informed consent form by subject
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, 18 years or older
Subjects undergoing a clinically indicated MRI examination. Examples of medical indications include known or suspected heart failure or cardiomyopathy, chest pain with known or suspected coronary artery disease, unexplained dyspnea, valve disease, known or suspected congenital heart disease, cardiac masses and known or suspected aortic disease, exposure to cardiotoxic drugs, and systemic illnesses with known associated cardiovascular involvement. Group B, Healthy volunteers enrolled for developmental testing and establishing reference values for the custom pulse sequences. In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, 18 years or older

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:
Unable to undergo magnetic resonance imaging because of:
Central nervous system aneurysm clips
Implanted neural stimulator
Implanted cardiac pacemaker or defibrillator
Cochlear implant
Ocular foreign body (e.g. metal shavings)
Implanted Insulin pump
Metal shrapnel or bullet unless any of the above objects have been cleared as safe for MRI according to the assessment present as clinical routine at the site.
For examinations that include contrast injection of GBCA: \-- renal excretory dysfunction, estimated glomerular filtration rate \<= 30 mL/min/1.73m(2) body surface area.(estimated glomerular filtration rate is only determined according to the institutional guidelines of patients at risk of renal dysfunction and may also depend upon the dose of GBCA administered). \-- Known allergic reactions to GBCA \-- Subjects may still be invited for non-contrast enhanced examinations or undergo MR examination with ferumoxytol as contrast agent. . For examinations that include contrast injection of ferumoxytol \-- Known allergic reactions to ferumoxytol or to mannitol excipient
For subjects with a planned pharmacological stress test with adenosine or regadenoson the following contraindications will be considered as exclusion criteria: --Bronchospastic lung disease with ongoing wheezing or history of significant reactive airway disease --Second- or third- degree atrioventricular blood, sinus node disease without a functioning MR conditional pacemaker --Systolic blood pressure \< 90 mmHg --Uncontrolled hypertension (systolic BP \> 200 mmHg or diastolic BP \> 110 mmHg) --Recent (\< 48hr) use of dipyridamole of dipyridamole- containing medications --Known hypersensitivity to adenosine or regadenoson.
Unstable angina, acute coronary syndrome, or less than 2- 4 days after an acute myocardial infarction
For regadenoson only: seizure disorder as regadenoson may lower seizure threshold. Aminophylline should not be used in cases of seizures associated with Regadenoson.
Pregnant Women.
Lactating Women for administration of GBCA unless the subjects is willing to discard the milk for 24 hours after receiving gadolinium In addition, the following exclusion criteria pertains to Group B, healthy volunteers to be considered for reference values:
Known history of major illness, including, but not limited to having a hypertension diagnosis in need of anti-hypertensive medication, myocardial infarction, diabetes, familial hypercholesterolemia, cardiomyopathy, congenital heart disease, moderate or severe valvular disease, cerebrovascular insult or peripheral vascular disease, symptoms of angina or dyspnea, current smoker.
Decisionally impaired individuals

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Washington Dc?

Yes, this clinical trial (NCT04927429) has an active research site in Washington Dc, DC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cardiovascular Disease Treatment Options in Washington Dc, DC

If you're searching for cardiovascular disease treatment options in Washington Dc, DC, this clinical trial (NCT04927429) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cardiovascular disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cardiovascular disease clinical trials near you to find additional studies recruiting in your area.

More Heart Disease Trials in Washington Dc, DC

See all heart disease clinical trials recruiting in Washington Dc — not just this study.

Browse Heart Disease Trials in Washington Dc

Ready to Join in Washington Dc?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Washington Dc, DC